Becky Leung

To the Editor: Allogeneic hematopoietic stem cell transplantation (allo-HSCT) is the only curative therapy for myelodysplastic syndromes (MDS) and optimising patients for transplant is critical to achieving the best outcomes [1, 2]. Hypomethylating agents (HMAs), particularly azacitidine, are used as a bridging strategy with the aim of achieving disease control and limiting leukemic transformation.

If you're an existing community leader looking to inject new life into your program, this workshop is for you. Spend the morning with Jive strategy consultants and your fellow veteran Jive customers to learn on advanced engagement strategies used across our customers. Breakout activities will allow you to share your most pressing problems and get practical advice from your peers. Chose from one of two breakout workshops covering internal or external communities below.